Literature DB >> 7622117

Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy.

Y C Lin1, A P Kudelka, D Tresukosol, A Malpica, C H Carrasco, D D Lawrence, R E Collier, A Munoz, L Delclos, J J Kavanagh.   

Abstract

We report the case of a patient who has a 23-year history of endometrial stromal sarcoma (ESS). She initially underwent tumor-reductive surgery followed by adjuvant radiotherapy. The pelvic tumor recurred nearly 8 years later, obstructing the ureter and directly invading the bladder. It propagated into the vena cava as a thrombus and finally spread into the right heart chambers, leading to cardiac failure 13 years after the recurrence. The patient was treated with hormonal therapy, multiple resections of the pelvic tumor, chemoembolization, and systemic chemotherapy with doxorubicin and cyclophosphamide. She developed recurrent intractable symptoms and was started on prolonged oral etoposide therapy, which stabilized the size of the pelvic tumor and relieved her symptoms for 3 years. Her quality of life has markedly improved without significant morbidity. We review the options for treating recurrent ESS and suggest that use of prolonged oral etoposide therapy warrants further study in this setting.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622117     DOI: 10.1006/gyno.1995.1223

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Endometrial stromal sarcomas: a retrospective analysis of 28 patients, single center experience for 20 years.

Authors:  Eun Ji Nam; Jae Wook Kim; Dae Woo Lee; Si Young Jang; Jong Wook Hong; Young Tae Kim; Jae Hoon Kim; Sunghoon Kim; Sang Wun Kim
Journal:  Cancer Res Treat       Date:  2008-03-31       Impact factor: 4.679

2.  Endometrial stromal sarcoma: A review of the literature.

Authors:  Geetha Puliyath; M Krishnan Nair
Journal:  Indian J Med Paediatr Oncol       Date:  2012-01

3.  Endometrial Stromal Sarcomas: A clinico-pathological analysis of 27 patients.

Authors:  Dae-Young Kim; Kyung-Taek Lim; Yong-Soon Kwon
Journal:  Pak J Med Sci       Date:  2013-01       Impact factor: 1.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.